Home / Pharmaceutical company intelligence
CRYSTOLITE PHARMACEUTICALS logo
Pharmaceutical company intelligence

CRYSTOLITE PHARMACEUTICALS

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad-area pharmaceutical manufacturer established in 2004, manufacturing and marketing pharmaceutical and healthcare products for domestic and export markets.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
Plot #1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad, Pakistan
Phone
+92 342 0022555
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000778 Crystolite Pharmaceuticals. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000778 130 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx130public portfolio records represented
REG105unique registrations represented
IDX23indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR125current validated price records
G70generic molecules in indexed catalogue
DF10dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage96%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage81%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixCRYSTOLITE PHARMACEUTICALSShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/crystolite-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives52 · 40%Dermatology22 · 17%Cardiovascular15 · 12%Oncology & immunology10 · 8%CNS & mental health9 · 7%Vitamins, minerals & nutrition7 · 5%Endocrine & metabolic7 · 5%Other therapeutic areas8 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioCRYSTOLITE PHARMACEUTICALSDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/crystolite-pharmaceuticalsGenerated 23 Sep 2026130presentationsTablet59 · 45%Capsule21 · 16%Lotion17 · 13%Cream9 · 7%Injection6 · 5%Syrup6 · 5%Other forms12 · 9%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionCRYSTOLITE PHARMACEUTICALSCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/crystolite-pharmaceuticalsGenerated 23 Sep 2026105comparable productsBelow peer median11 · 10%Near peer median50 · 48%Above peer median44 · 42%Company median price position+4.0%Lowest-price equivalents10Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsCRYSTOLITE PHARMACEUTICALSCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/crystolite-pharmaceuticalsGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,37 shared53% overlapValor Pharmaceuticals36 shared51% overlapMediate Pharmaceutical Pvt Ltd34 shared49% overlapNeutro Pharma (Pvt.) Ltd.,34 shared49% overlapPharmasol (Pvt) Ltd.33 shared47% overlapShaigan Pharmaceuticals (Pvt) Ltd32 shared46% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives52 products · 40%
Dermatology22 products · 17%
Cardiovascular15 products · 12%
Oncology & immunology10 products · 8%
CNS & mental health9 products · 7%
Vitamins, minerals & nutrition7 products · 5%
Endocrine & metabolic7 products · 5%
Gastrointestinal & hepatology5 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antifungals13 products · 10%
Antivirals13 products · 10%
Retinoids / anti-acne medicines9 products · 7%
Topical corticosteroids / anti-inflammatory dermatologics9 products · 7%
Third-generation cephalosporins9 products · 7%
Calcium-channel blockers8 products · 6%
Immunosuppressants / immunomodulators8 products · 6%
Vitamins / minerals / hematinics7 products · 5%
Formulation footprint

Dosage forms

Tablet59 products
Capsule21 products
Lotion17 products
Cream9 products
Injection6 products
Syrup6 products
Gel4 products
Sachet3 products
Suspension3 products
Ointment2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ZuckerEmpagliflozin 7presentations 12.5 mg, 5 mg · Tablet #2 OrataneIsotretinoin 5presentations 10 mg, 20 mg · Capsule #3 Bptin-HAmlodipine + Valsartan + Hydrochlorothiazide 4presentations 10 mg + 25 mg + 160 mg, 10 mg + 25 mg + 320 mg, 5 mg + 12.5 mg + 160 mg, 5 mg + 25 mg + 160 mg · Tablet #4 RomlusTacrolimus 4presentations 0.5 mg, 1 mg · Capsule #5 CanixClotrimazole 3presentations 1%, 10 mg/mL, 10 mg/mL (1%) · Cream, Lotion #6 EcozoneCefotaxime 3presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1110% of comparable products
Near market median50within ±5% of median
Above market median4442% of comparable products
Lowest-price equivalents10ties included
Company median price position +4.0% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
C-Val Plus 80 mgHydrochlorothiazide · Tablet · 28’s PKR 24.18/tablet-53.2% vs market median Oratane 20 mgIsotretinoin · Capsule · 30's PKR 109.79/capsule-13.0% vs market median Epiwin 250 mg/5 mLSodium valproate · Syrup · 60ml PKR 1.62/mL-11.8% vs market median Zanzara 250 mgChloroquine · Tablet · 500’s PKR 1.43/tablet-8.9% vs market median Oracea 100 mgDoxycycline · Tablet · 30’s PKR 7.31/tablet-8.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 37shared generics Valor Pharmaceuticals219 products · 97 generics 36shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 34shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 34shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 33shared generics Shaigan Pharmaceuticals (Pvt) Ltd198 products · 74 generics 32shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers105Distinct registrations among indexed, published, presentation-validated products only
Verified price observations130
Products with a verified price130
Products with multiple price observations0
Source records with multiple versions130
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

105 unique registration(s) · 23 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Therapeutic areaDermatology Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Asset Acitretin 25 mg Capsule 30’s 077615 PKR 2,546.20 PKR 84.87/capsule 6% below median
Calpsor Calcipotriol 50 mcg/mL Lotion 30ml 077719 PKR 1,519.57 PKR 50.65/mL No comparator
Calpsor-B Calcipotriol + Betamethasone 50 mcg/mL + 500 mcg/mL Lotion 30ml 077720 PKR 1,502.41 PKR 50.08/mL No comparator
Canix-H Hydrocortisone 10 mg Cream 10gm 077636 PKR 114.05 PKR 11.41/g No comparator
Canix-H Hydrocortisone 10 mg/g Cream 20gm 077636 PKR 210.42 PKR 10.52/g No comparator
Cosalic Salicylic acid + Coal tar + Hydrocortisone 3% + 3% + 1% Lotion 60ml 077653 PKR 613.95 PKR 10.23/mL Near median
Cosalic Salicylic acid + Coal tar + Hydrocortisone 3% + 3% + 1% Lotion 30ml 077653 PKR 323.13 PKR 10.77/mL 5% above median
Differin Adapalene + Benzoyl peroxide 0.1% + 2.5% Gel 15gm 077633 PKR 324.53 PKR 21.64/g No comparator
Differin Benzoyl peroxide 0.1% Gel 30gm 077633 PKR 584.93 PKR 19.50/g No comparator
Muricin Mupirocin 2% Ointment 15gm 077628 PKR 217.73 PKR 14.52/g Near median
No Boyle B Fusidic acid + Betamethasone valerate 2% + 0.1% Cream 15gm 085764 PKR 342.15 PKR 22.81/g No comparator
No-Boyle-H Fusidic acid + Hydrocortisone acetate 2% + 1% Cream 15gm 077637 PKR 399.17 PKR 26.61/g No comparator
Oratane Isotretinoin 10 mg Capsule 10’s 077616 PKR 716.45 PKR 71.65/capsule Near median
Oratane Isotretinoin 20 mg Capsule 30's 077617 PKR 3,293.67 PKR 109.79/capsule 13% below median
Oratane Isotretinoin 20 mg Capsule 10’s 077617 PKR 1,193.42 PKR 119.34/capsule 5% below median
Oratane Isotretinoin 10 mg Capsule 6x5’s 082469 PKR 2,396.66 PKR 79.89/capsule 6% above median
Oratane Isotretinoin 20 mg Capsule 6x5’s 082470 PKR 3,994.42 PKR 133.15/capsule 6% above median
Oratraxin Isotretinoin 0.5 mg Gel 10gm 077632 PKR 437.19 PKR 43.72/g No comparator
Valisone -S Betamethasone + Salicylic acid 0.5 mg + 30 mg Ointment 15gm 077642 PKR 100.16 PKR 6.68/g 5% above median
Valisone -S Betamethasone + Salicylic acid 0.05% w/v + 3% w/v Lotion 60ml 077648 PKR 280.22 PKR 4.67/mL 8% below median
Valisone-S Betamethasone + Salicylic acid 0.05% w/v + 3% w/v Lotion 25ml 077648 PKR 126.55 PKR 5.06/mL 8% above median
Wart-Off Salicylic Acid 167 mg Lotion 15ml 077722 PKR 391.56 PKR 26.10/mL No comparator
Wart-Off Salicylic acid + Lactic acid 167 mg/mL + 167 mg/mL Lotion 30ml 077722 PKR 743.22 PKR 24.77/mL No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). CRYSTOLITE PHARMACEUTICALS — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/crystolite-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.